News and Developments

  • February, 2023: Senex is granted US patent 11,572,369 covering the composition of matter of new selective Mediator kinase inhibitors and their uses for cancer therapy.
  • December, 2022: A study by Senex and collaborators “Dual therapeutic targeting of CDK8/19 and mTOR in triple negative breast cancer” is presented at the San Antonio Breast Cancer Symposium.
  • September, 2022: Senex wins Phase I SBIR grant R43CA271996 from the National Cancer Institute in support of its breast cancer drug development program.
  • August, 2022: an article in Proc Natl Acad Sci USA 2022 Aug 9; 119(32):e2201073119. doi: 10.1073/pnas.2201073119 reports that Senex’s Mediator kinase inhibitors sensitize HER2-positive breast cancers to HER2-targeting drugs, preventing the development of resistance and overcoming the already established resistance to such drugs, both in vitro and in vivo.
  • July, 2022: Dennis Goldberg, PhD joins Senex as Chief Executive Officer. Dr. Goldberg is a senior executive with more than 30 years of leadership experience in the pharmaceutical and biotechnology industries, with a track record of success spanning drug discovery and development, regulatory affairs and executive management.
  • April, 2022: A study by Senex and collaborators “Inhibition of CDK8/19 Mediator kinase suppresses primary and metastatic growth of castration-resistant prostate cancer” is presented at the Annual Meeting of the American Association for Cancer Research in New Orleans.
  • March, 2022: Senex wins Translational Science Award W81XWH2210205 from the Department of Defense Congressionally Directed Medical Research Program, Prostate Cancer Research Program, in support of its prostate cancer drug development.
  • February, 2022: an article in J Med Chem 65(4):3420-3433 https://doi.org/10.1021/acs.jmedchem.1c01951 describes a new series of Senex’s Mediator kinase inhibitors with tumor-enriched pharmacokinetics.
  • August, 2021: George Wilding, MD, who joined Senex in February as Senior Medical Advisor, has assumed the position of Chief Medical Officer.
  • May, 2021: Senex is granted US patent 11,014,906 covering the composition of matter of a new chemical series of selective Mediator kinase inhibitors.
  • May, 2021: Senex is granted US patent 10,993,945 covering the use of Mediator kinase inhibitors for the treatment of breast cancer.
  • February, 2021: George Wilding, MD joins Senex as Senior Medical Advisor. Dr. Wilding has served as Vice President and Deputy Chief Academic Officer at The University of Texas MD Anderson Cancer Center and as Director of Cancer Center and Head of Hematology-Oncology Division at the University of Wisconsin Carbone Comprehensive Cancer Center.
  • January, 2021: an article in Nucleic Acids Research, gkaa1289, https://doi.org/10.1093/nar/gkaa1289 reports that Senex’s Mediator kinase inhibitors increase tumor cell killing by an alkylating agent. 
  • January, 2021: an article in Cells  10, 144 https://doi.org/10.3390/cells10010144 reports that Senex’s Mediator kinase inhibitors prevent the development of resistance to EGFR-targeting anticancer drugs.
  • December, 2020: Senex’s new Mediator kinase inhibitor drug candidate enters the stage of GMP manufacturing. 
  • August, 2020: Dr. Dani Bolognesi, the developer of a leading antiretroviral drug, joins Senex Board of Directors.
  • June, 2020: an article in Viruses   2020, 12, 654 https://doi.org/10.3390/v12060654 reports that Senex’s Mediator kinase inhibitors inhibit Dengue virus replication. 
  • June, 2020: Senex wins Phase II SBIR grant R44CA203184 from the National Cancer Institute in support of its prostate cancer drug development program.
  • March, 2020: Senex is granted US patent 10,584,369, covering a general cell-based method for measuring the activity of a protein inhibitor.
  • August, 2019: an article in Front. Immunol., https://doi.org/10.3389/fimmu.2019.01988 reports that Senex’s Mediator kinase inhibitors promote Treg cell differentiation, suggesting utility for the treatment of autoimmune diseases.
  • February, 2019: an article in J. Cell. Physiol., https://doi.org/10.1002/jcp.28321 reports that Senex’s Mediator kinase inhibitors promote cancellous bone regeneration, suggesting utility for the treatment of osteoporosis.
  • September, 2018: an article in Cancer Research 78, 6594-6606 (2018) https://doi.org/10.1158/0008-5472.CAN-18-1583 reports that Senex’s Mediator kinase inhibitors suppress metastatic growth of colon cancers.
  • April, 2018: an article in Oncogene 78, 6594-6606 (2018) https://doi.org/10.1038/s41388-018-0316-y reports that Senex’s Mediator kinase inhibitors suppress invasive growth of tumors.
  • September, 2017: an article in Proc. Natl. Acad. Sci. USA 114, 10208-10213 (2017) https://doi.org/10.1073/pnas.1710467114 identifies Mediator kinase as a general mediator of transcriptional reprogramming, a key event in cancer drug resistance, metastasis and other pathological processes.
  • September, 2017: Senex wins Phase I SBIR grant R43HL137525 from the National Heart, Lung, and Blood Institute in support of its program to improve the efficacy of vascular surgery.
  • July, 2017: Senex wins Phase I SBIR grant R43CA221485 from the National Cancer Institute in support of its program for the treatment of HER2-positive breast cancer.
  • May, 2017: Senex is an exclusive licensee of a newly granted US patent 9,636,342, covering the use of Mediator kinase inhibitors for the treatment of prostate cancer.
  • January, 2017: an article in Oncotarget 8, 12558-12575 (2017)  https://doi.org/10.18632/oncotarget.14894 reports that Senex’s Mediator kinase inhibitors suppress in vitro and in vivo growth of hormone receptor-positive breast cancers.
  • December, 2016: Senex wins Phase I SBIR grant R43CA213629 from the National Cancer Institute in support of its program for the treatment of leukemia.
  • August, 2016: Senex is granted US patent 9,409,873, covering the composition of matter of selective Mediator kinase inhibitors.
  • April, 2016: Senex is highlighted in a BioWorld Insight article that appeared on April 25th.
  • April, 2016: Senex is granted US patent 9,321,737, covering the composition of matter of selective Mediator kinase inhibitors.
  • September, 2015: Senex wins Phase I SBIR grant R43CA203184 from the National Cancer Institute in support of its program for the treatment of prostate cancer.
  • January, 2014: Senex establishes a strategic partnership with a foreign company to develop Senex’s lead Mediator kinase inhibitor as a cancer therapeutic agent in the foreign partner’s territory.
  • December, 2013: Senex is granted US patent 8,598,344, covering the composition-of-matter of selective Mediator kinase inhibitors.
  • November, 2013: Senex is granted US patent 8,592,147, covering its drug discovery methodology.
  • August, 2013: SCRA Technology Ventures invests in Senex
  • August, 2012: an article in Proc. Natl. Acad. Sci. USA 109, 13799-13804 (2012)  https://doi.org/10.1073/pnas.1206906109 describes the discovery of the first selective Mediator kinase inhibitors by Senex.
  • September, 2011: Senex wins Phase II SBIR grant R44CA141845 from the National Cancer Institute in support of its program for the development of CDK3 inhibitors.
  • July, 2011: an article in Proc. Natl. Acad. Sci. USA 108, 12449-12454 (2011) https://doi.org/10.1073/pnas.1103842108 describes the identification of COPZ1 as a novel drug target for a wide variety of cancers.
  • May, 2011: Senex relocates to Columbia, SC, with the help of an investment from SC Launch. 
  • October, 2010:  Senex is awarded Therapeutic Discovery Project Grant by the United States Affordable Care Act of 2010.
  • September, 2009: Senex wins ARRA Supplement to Phase II SBIR grant R44CA139991 from the National Cancer Institute.
  • June, 2009: Senex wins Phase I SBIR grant R43CA141845 from the National Cancer Institute in support of its program for the development of CDK3 inhibitors.
  • September, 2008: Senex wins Phase II SBIR grant R44CA139991 from the National Cancer Institute in support of its program for the development of inhibitors of tumor-promoting activities of senescent cells.
  • August, 2008: Senex wins Department of Defense Breast Cancer Concept Award W81XWH0810611 in support of its program for the development of inhibitors of tumor-promoting activities of stromal fibroblasts.
  • January, 2008: Senex wins Phase I SBIR grant R43GM081968 from the National Institute of General Medical Sciences in support of its program for the development of small molecules inducing BTG1 expression.
  • January, 2007: Senex wins Award ADDF261113 from Alzheimer’s Drug Discovery Foundation in support of its program for the development of inhibitors of the expression of genes implicated in Alzheimer’s Disease. 
  • July, 2006: Senex wins Phase I SBIR grant R43AG029023 from the National Institute of Aging in support of its program for the development of inhibitors of tumor-promoting activities of senescent cells.
%d bloggers like this: